KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial.

Matthias Guckenberger, Lotte Wilke, Charlotte Billiet, Susanne Rogers, Ciro Franzese, Daniel Schnell, Mateusz Spałek, Daniel M Aebersold, Hossein Hemmatazad, Thomas Zilli, Judit Boda-Heggemann, Brigitta G Baumert, Jean-Jacques Stelmes, Franziska Nägler, Philipp Gut, Christian Weiß, Alessio Bruni, Frank Zimmermann, Robert Förster, Jörg Zimmer, Indira Madani

Radiother Oncol 208 110940

PMID40378895
PMCID-
DOI10.1016/j.radonc.2025.110940
发表日期2025-05-16
入排依据:The study is an original Phase III randomized trial in oncology with time-to-event efficacy (OS, local failure), but the intervention is radiotherapy (SBRT), not a drug-containing therapy. Therefore, it does not meet the drug intervention criterion.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: To prospectively evaluate safety and efficacy of dose-intensified multifraction SBRT using a simultaneous-integrated boost concept for vertebral oligometastases. MATERIAL AND METHODS: Data from 128 patients with 143 vertebral oligometastases (≤5 distant metastases in total) treated with dose-intensified SBRT (48.5 Gy/10 [with epidural involvement] or 40 Gy/5 [without epidural involvement]) in the randomized and non-randomized arms of a phase 3 clinical trial conducted at 18 international centers between 2016 and 2023 were analyzed. RESULTS: The median age of all patients was 68 years; 77 patients (60.2%) had breast and prostate cancer. Of 143 vertebral metastases, 23 (16.1%) and 22 metastases (15.4%) had epidural and paraspinal tumor involvement, respectively. The median follow-up time was 24 months. At 2 years, cumulative incidence of local failure (4 failures) was 5.3%. There were 4 (2.8%) baseline and 8 (5.6%) de novo vertebral compression fractures (VCFs). Two-year OS was 82.2% (95% CI, 74.9-89.6%). There was no grade ≥ 4 adverse events (AE) and the crude rate of grade 3 AEs was 5.5%; no myelopathy or plexopathy was observed. On multivariate analysis, only non-breast or non-prostate cancer (HR, 7.91; 95%, CI 1.79-35.03; 2-sided P = 0.01) were found to be prognostic for adverse OS. No prognostic factors for VCF were identified. Epidural and paraspinal involvement were not found to be prognostic for treatment outcome. CONCLUSIONS: Dose-intensified SBRT for vertebral oligometastases is effective and safe, even in high-risk patients with epidural or paraspinal involvement.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。